Ukuhlolwa kungasiza ngokuxilongwa uma izimpawu zingavamile
I-anti-Müllerian hormone (AMH), eyaziwa nangokuthi i-Müllerian inhibiting substance, uhlobo lwama-hormone elifihliwe yi-follicle yama-ovari njengoba ikhula. Amazinga e-AMH ayingxenye ebalulekile yokuxilongwa njengoba ahlobana ngokuqondile nenani lezintambo ezithandwayo ezitholakala ku-ovary inyanga ngayinye.
I-Antral follicles, ebizwa nangokuthi i-follicles yokuphumula, yilabo abasesiteji sokugcina sokuthuthukiswa.
Ngamunye unethuba lokukhulula iqanda uma livuthiwe ngokugcwele.
Odokotela bangase bahlole amazinga e-AMH ngezizathu eziningana. Phakathi kwabo, inani langempela le-follicles-elibhekwa njenge-ovarian reserve-linganika odokotela umbono wokuthi indlela ephumelelayo ekukhuliseni i-vitro fertilization (IVF) ingaba ngayo. Ukuphakama kwe-antral follicle count, izinga eliphezulu le-AMH. Inhlangano inenani eliphezulu lokubikezela kulokhu.
I-AMH Nemiphumela Yayo ku-PCOS
Ngakolunye uhlangothi, lezi zinyathelo ezifanayo zingaba inkinga kwabesifazane abane- polycystic ovary syndrome (PCOS) . Abesifazane abane-PCOS bavame ukuba nenombolo ephezulu ye-antlic follicles futhi, ngenxa yalokho, izinga eliphakeme elilinganayo le-AMH egazini labo.
Inkinga ngalokhu ukuthi i-AMH kakhulu ingakwazi ukuyeka ukukhipha ovulation ukuba ingenzeki. Esikhathini esibelethweni esijwayelekile, i-AMH isebenza ngokuvimbela ukuthuthukiswa kwesikhashana ngaphambi kobuciko futhi, futhi, ukukhululwa kweqanda elivuthiwe ngesikhathi sokuvuthwa. Lapho amazinga e-AMH ephezulu kakhulu, angakwazi ukubeka ngokungabonakali amabhuleki kule nqubo, ukuvimbela ukuvuthwa kweqanda phakathi komfula.
Ngendlela efanayo ne-AMH engasiza ukubikezela ukuthi kungenzeka kanjani inqubo ephumelelayo ye-IVF, ingasiza ukuxilonga i-PCOS kwabesifazane abangenayo izimpawu ezicacile ze-syndrome.
Yeka ukuthi i-AMH Test Can Tell Us
Amazinga we-AMH angalinganiswa nokuhlolwa kwegazi okulula. Igazi lingadonselwa kunoma yiluphi usuku lokujikeleza esikhathini, futhi emva kwalokho, luthunyelwe ebhodini lokuhlaziywa.
Uma ibuyiselwe, imiphumela ingasitshela ukuthi i-AMH iphezulu, iphansi, noma evamile.
- Amazinga aphakeme angaphezu kuka-5.0 ng / ml.
- Ukuphakama kwe-border line phakathi kuka 3.5 ng / ml kuya ku-5.0 ng / ml.
- Okujwayelekile kuphakathi kuka-0.7ng / ml kuya ku-3.5ng / ml.
- I-Borderline low iphakathi kuka-0.3 ng / ml kuya ku-0.7 ng / ml.
- Amazinga aphansi angaphansi kuka-0.3 ng / ml.
Izinga eliphakeme kuphela alikwazi ukuxilonga i-PCOS kusukela kumazinga we-AMH ayancipha ngokweminyaka. Ngenxa yalokho, odokotela bazoqhathanisa iminyaka yobudala besifazane kanye nemiphumela ye-AMH futhi basebenzise labo ukusiza ukuxilongwa.
Uma i-AMH ibalulekile ekuboneni i-PCOS
I-AMH ingaba usizo kakhulu ekuhloleni i-PCOS, ikakhulukazi kwabesifazane abangaphezu kuka-35. Ngokuvamile, ukuqinisekisa ukuthi i-PCOS ixilongwa, owesifazane kuzodingeka ahlangabezane nezinqubo ezimbili zokuhlonza:
- I-ovulation echelile
- I-Polycystic ovaries ekuhlolweni kwe-ultrasound
- I-Lab imiphumela ekhombisa ukwanda kwamahomoni athile ahambisana nezimpawu ze-PCOS (kufaka phakathi i-hirsutism, i-acne, ukulahleka kwezinwele, njll.)
Inkinga ngalokhu ukuthi ama-ovaries ama-polycystic e-ultrasound ajwayelekile kubantu besifazane abane-PCOS ngemuva kweminyaka engama-35. Ngakho-ke, uma ezinye izimpawu zingacacile, ukuxilongwa kwe-PCO kungase kungabikho noma kuthathwe njengokungacabangi.
Ngokuthatha i-AMH ephakeme, odokotela ngezinye izikhathi bangasekela ukuxilongwa ngokuqiniseka. Nakuba ukuhlolwa kungabhekwa njengengxenye esikhundleni se-polycystic ovary ultrasound, kunenani lokuhlola ngokuhambisana nezinye izivivinyo.
Ngaphezu kwalokho, kwabesifazane abaziwa ukuthi babe ne-PCOS, amazinga e-AMH aphakeme ahambisana nokukhula okukhulu kwezimpawu, okwenza ukusetshenziswa kwawo kubaluleke kakhulu ekuhloleni nasekuhloleni izifo ezihlobene ne-PCOS.
> Umthombo:
> Dumont, A .; U-Robin, G .; Catteau-Jonard, S. et al. "Indima ye-Anti-Müllerian Hormone ekuthatheni i-pathophysiology, ukuxilongwa, nokuphathwa kwe-Polycystic Ovary Syndrome: Ukubuyekeza." I-Reprod Biol Endocrinol. 2015; 13 (1): 137.